Literature DB >> 11523046

Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation.

J Flier1, D M Boorsma, P J van Beek, C Nieboer, T J Stoof, R Willemze, C P Tensen.   

Abstract

Recruitment of activated T-cells to the skin is a common feature in a wide variety of inflammatory skin diseases. As CXCR3 activating chemokines CXCL10 (IP-10), CXCL9 (Mig), and CXCL11 (IP-9/I-TAC) specifically attract activated T-cells, this study addressed the question of whether differences in the expression of these chemokines correlate with the site and cellular composition of the skin infiltrates in different types of inflammatory skin disease. Skin biopsies from lichen planus, chronic discoid lupus erythematosus, allergic patch test reactions, psoriasis, and Jessner's lymphocytic infiltration of the skin were investigated for chemokine expression using RNA in situ hybridization, and for the expression of CXCR3 using immunohistochemistry. The results showed differential expression of CXCL10, CXCL9, and CXCL11, which correlated with differences in the localization and cellular composition of the infiltrates. Whereas CXCL10 and CXCL11 were mainly expressed by basal keratinoctyes, CXCL9 mRNA expression was located predominantly in the dermal infiltrates. Correlation with immunohistochemical data suggested that macrophages and activated keratinocytes were the main producers of these chemokines. CXCR3 was expressed by a majority of both CD4+ and CD8+ infiltrating T-cells, suggesting a functional interaction between locally produced chemokines and CXCR3-expressing T-cells. In conclusion, these findings indicate that these CXCR3 activating chemokines play a significant role in the recruitment and maintenance of T-cell infiltrates in the inflammatory skin diseases studied. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11523046     DOI: 10.1002/1096-9896(200108)194:4<397::aid-path899>3.0.co;2-s

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  88 in total

1.  Langerhans cells renew in the skin throughout life under steady-state conditions.

Authors:  Miriam Merad; Markus G Manz; Holger Karsunky; Amy Wagers; Wendy Peters; Israel Charo; Irving L Weissman; Jason G Cyster; Edgar G Engleman
Journal:  Nat Immunol       Date:  2002-11-04       Impact factor: 25.606

2.  T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking.

Authors:  P Kivisäkk; C Trebst; Z Liu; B H Tucky; T L Sørensen; R A Rudick; M Mack; R M Ransohoff
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

Review 3.  The pathogenesis of primary cicatricial alopecias.

Authors:  Matthew J Harries; Ralf Paus
Journal:  Am J Pathol       Date:  2010-10-01       Impact factor: 4.307

4.  Dendritic cells derived from preeclampsia patients influence Th1/Th17 cell differentiation in vitro.

Authors:  Jing Wang; Yu-Mei Tao; Xiao-Yan Cheng; Tian-Feng Zhu; Zhi-Fang Chen; Hui Yao; Liang-Xiang Su
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 5.  CXCR3 ligands: redundant, collaborative and antagonistic functions.

Authors:  Joanna R Groom; Andrew D Luster
Journal:  Immunol Cell Biol       Date:  2011-01-11       Impact factor: 5.126

6.  Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus.

Authors:  K O Kong; A W Tan; B Y H Thong; T Y Lian; Y K Cheng; C L Teh; E T Koh; H H Chng; W G Law; T C Lau; K P Leong; B P Leung; H S Howe
Journal:  Clin Exp Immunol       Date:  2009-01-23       Impact factor: 4.330

Review 7.  Chemokine receptor antagonists: overcoming developmental hurdles.

Authors:  Richard Horuk
Journal:  Nat Rev Drug Discov       Date:  2008-12-12       Impact factor: 84.694

8.  Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines.

Authors:  Edmund K Moon; Liang-Chuan S Wang; Kheng Bekdache; Rachel C Lynn; Albert Lo; Stephen H Thorne; Steven M Albelda
Journal:  Oncoimmunology       Date:  2018-01-09       Impact factor: 8.110

Review 9.  The Beginning of the End: CXCR3 Signaling in Late-Stage Wound Healing.

Authors:  Arthur C Huen; Alan Wells
Journal:  Adv Wound Care (New Rochelle)       Date:  2012-12       Impact factor: 4.730

10.  ELR-negative CXC chemokine CXCL11 (IP-9/I-TAC) facilitates dermal and epidermal maturation during wound repair.

Authors:  Cecelia C Yates; Diana Whaley; Amy Y-Chen; Priya Kulesekaran; Patricia A Hebda; Alan Wells
Journal:  Am J Pathol       Date:  2008-07-31       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.